Search for: "WARNER CHILCOTT US, LLC"
Results 1 - 14
of 14
Sorted by Relevance
|
Sort by Date
19 Aug 2012, 11:28 am
LLC; Warner Chilcott (US) LLC; Warner Chilcott PLC Infringement of U.S. [read post]
31 Dec 2015, 8:16 pm
Warner Chilcott (US), LLC et al. v. [read post]
11 Apr 2010, 9:36 pm
Warner Chilcott Co. [read post]
13 Mar 2012, 7:14 pm
Boissonault:During our June 22 to July 29, 2011 inspection of your pharmaceutical manufacturing facility, Warner Chilcott Company, LLC, located at Road 195, Km. 1.1, Union Street, Fajardo, Puerto Rico, an investigator from the Food and Drug Administration (FDA) identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals, Title 21, Code of Federal Regulations, Parts 210 and 211. [read post]
23 Nov 2015, 2:05 pm
Sales LLC, a subsidiary of pharmaceutical manufacturer Warner Chilcott PLC, has agreed to plead guilty to a felony charge of health care fraud, the Justice Department announced today. [read post]
13 Dec 2011, 5:39 am
In other words, the court’s primary focus was on the question of whether Warner Chilcott was likely to succeed on the merits of its infringement claim, a question which turned on a battle of experts. [read post]
9 Oct 2009, 9:11 am
9/9: Warner Chilcott Company LLC v. [read post]
25 Jul 2011, 10:48 am
Bisphosphonates for the treatment and prevention of osteoporosis include: FOSAMAX (alendronate sodium) tablets and solution and FOSAMAX PLUS D (alendronate sodium/cholecalciferol) tablets, Merck & Co., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche… [read post]
8 Sep 2011, 11:04 am
According to the FDA's Announcement for this September 2011 meeting, these two advisory committees will consider the benefits and risks of long-term use of osteoporosis medications in the bisphosphonate class of drugs, which were identified by the FDA as: FOSAMAX (alendronate sodium) tablets and solution and FOSAMAX PLUS D (alendronate sodium/cholecalciferol) tablets, Merck & Co., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release… [read post]
10 May 2011, 1:31 pm
we couldn’t help but notice a recent Untitled Letter to Warner Chilcott, LLC, relating to a YouTube video. [read post]
20 Mar 2009, 6:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Reps Eshoo, Inslee and Barton introduce Pathway for Biosimilars Act (FDA Law Blog) (Patent Docs) (Patent Baristas) (Patent Baristas) (Law360) US: Reps Waxman, Pallone, Deal and Emerson introduce Promoting Innovation and Access to Life-Saving Medicine Act (Intellectual Property Watch) (IPKat) (Patent Docs) EU: Pharma… [read post]
1 Apr 2010, 3:04 am
USPTO and Myriad Genetics (Docket Report) (Peter Zura's 271 Patent Blog) (Inventive Step) (Patently-O) (Holman's Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art) US: Study suggests USPTO erred in broad claims of Myriad BRCA1 patent (Tech Transfer Blog) (Patent Docs) US: CAFC confirms written description requirement in Ariad v Lilly (IP Law Blog) (IP Osgoode) (IP Spotlight) (Ars… [read post]
10 Feb 2010, 4:47 pm
Xenotech, LLC et al. [read post]
22 Dec 2010, 3:01 am
LLC et al. v. [read post]
